NEW YORK (GenomeWeb) – Agilent Technologies announced that the US Food and Drug Administration has granted expanded approval to the firm's companion diagnostic for the Merck PD-L1 inhibitor Keytruda (pembrolizumab). The Dako PD-L1 IHC 22C3 pharmDx test can now be used to determine expression status and inform treatment in a broader range of metastatic non-small cell lung cancer (NSCLC) patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.